Cargando…

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study

BACKGROUND: The integrase inhibitor dolutegravir could have a major role in future antiretroviral therapy (ART) regimens in sub-Saharan Africa because of its high potency and barrier to resistance, good tolerability, and low cost, but there is uncertainty over appropriate policies for use relating t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phillips, Andrew N, Venter, Francois, Havlir, Diane, Pozniak, Anton, Kuritzkes, Daniel, Wensing, Annemarie, Lundgren, Jens D, De Luca, Andrea, Pillay, Deenan, Mellors, John, Cambiano, Valentina, Bansi-Matharu, Loveleen, Nakagawa, Fumiyo, Kalua, Thokozani, Jahn, Andreas, Apollo, Tsitsi, Mugurungi, Owen, Clayden, Polly, Gupta, Ravindra K, Barnabas, Ruanne, Revill, Paul, Cohn, Jennifer, Bertagnolio, Silvia, Calmy, Alexandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361866/ https://www.ncbi.nlm.nih.gov/pubmed/30503325 http://dx.doi.org/10.1016/S2352-3018(18)30317-5

Ejemplares similares

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
por: Phillips, Andrew N, et al.
Publicado: (2020)

Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa
por: Phillips, Andrew N, et al.
Publicado: (2016)

Point-of-Care Viral Load Testing for Sub-Saharan Africa: Informing a Target Product Profile
por: Phillips, Andrew N., et al.
Publicado: (2016)

Potential Impact and Cost-Effectiveness of Condomless-Sex–Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance
por: Phillips, Andrew N, et al.
Publicado: (2019)

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study
por: Phillips, Andrew N, et al.
Publicado: (2017)

90‐90‐90 by 2020? Estimation and projection of the adult HIV epidemic and ART programme in Zimbabwe – 2017 to 2020
por: Bansi‐Matharu, Loveleen, et al.
Publicado: (2018)

The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis
por: Phillips, Andrew N, et al.
Publicado: (2021)

Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa
por: Phillips, Andrew N., et al.
Publicado: (2017)

Cost‐per‐diagnosis as a metric for monitoring cost‐effectiveness of HIV testing programmes in low‐income settings in southern Africa: health economic and modelling analysis
por: Phillips, Andrew N, et al.
Publicado: (2019)

Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa
por: Phillips, Andrew N., et al.
Publicado: (2016)

Cost-effectiveness of voluntary medical male circumcision for HIV prevention across sub-Saharan Africa: results from five independent models
por: Bansi-Matharu, Loveleen, et al.
Publicado: (2022)

Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure
por: Shroufi, Amir, et al.
Publicado: (2019)

Assessment of the Potential Impact and Cost-effectiveness of Self-Testing for HIV in Low-Income Countries
por: Cambiano, Valentina, et al.
Publicado: (2015)

Strengthening the scale‐up and uptake of effective interventions for sex workers for population impact in Zimbabwe
por: Cowan, Frances M, et al.
Publicado: (2019)

Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income Settings
por: Phillips, Andrew, et al.
Publicado: (2014)

Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models
por: Bershteyn, Anna, et al.
Publicado: (2022)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

Cost‐effectiveness of routine viral load monitoring in low‐ and middle‐income countries: a systematic review
por: Barnabas, Ruanne V, et al.
Publicado: (2017)

Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study
por: Phillips, Andrew N, et al.
Publicado: (2022)

Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring
por: von Wyl, Viktor, et al.
Publicado: (2012)

Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review
por: Hill, Andrew, et al.
Publicado: (2018)

Weight gain on dolutegravir: Association is not the same as causation
por: Maartens, Gary, et al.
Publicado: (2023)

A quantitative assessment of the consistency of projections from five mathematical models of the HIV epidemic in South Africa: a model comparison study
por: Moolla, Haroon, et al.
Publicado: (2023)

Stable HIV‐1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study
por: Sculier, D, et al.
Publicado: (2018)

Characteristics and treatment outcomes of tuberculosis patients who “transfer-in” to health facilities in Harare City, Zimbabwe: a descriptive cross-sectional study
por: Takarinda, Kudakwashe C, et al.
Publicado: (2012)

Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects
por: Mofenson, Lynne M, et al.
Publicado: (2019)

Treatment outcomes of adult patients with recurrent tuberculosis in relation to HIV status in Zimbabwe: a retrospective record review
por: Takarinda, Kudakwashe C, et al.
Publicado: (2012)

1498. Geographic differences in weight change on dolutegravir: a prospective cohort study
por: Chen, Geoffrey, et al.
Publicado: (2023)

Gender-related differences in outcomes and attrition on antiretroviral treatment among an HIV-infected patient cohort in Zimbabwe: 2007–2010
por: Takarinda, Kudakwashe C., et al.
Publicado: (2014)

Sociodemographic differences in symptom severity and duration among women referred to secondary care for menorrhagia in England and Wales: a cohort study from the National Heavy Menstrual Bleeding Audit
por: Kiran, Amit, et al.
Publicado: (2018)

Factors associated with receiving surgical treatment for menorrhagia in England and Wales: findings from a cohort study of the National Heavy Menstrual Bleeding Audit
por: Geary, Rebecca Sally, et al.
Publicado: (2019)

Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis
por: Wandeler, Gilles, et al.
Publicado: (2019)

The risks and benefits of providing HIV services during the COVID-19 pandemic
por: Stover, John, et al.
Publicado: (2021)

Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women
por: Huntington, Susie E, et al.
Publicado: (2012)

The promise of paediatric dolutegravir
por: Golin, Rachel, et al.
Publicado: (2021)

Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV
por: Mondleki, Enkosi, et al.
Publicado: (2022)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care
por: Revill, Paul, et al.
Publicado: (2018)

Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses
por: Marije Hofstra, Laura, et al.
Publicado: (2014)

Patient Retention, Clinical Outcomes and Attrition-Associated Factors of HIV-Infected Patients Enrolled in Zimbabwe's National Antiretroviral Therapy Programme, 2007–2010
por: Mutasa-Apollo, Tsitsi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5ae883nf8fkgkk7ujpnef4ipo0